4F-MPH 30 mg en pastillas (4-fluorometilfenidato)
4F-MPH 30 mg en pastillas (4-fluorometilfenidato) Rango de precios: desde €18.95 hasta €549.95
Volver a productos
Papel secante 1cP-MiPLA 200 MCG
Papel secante 1cP-MiPLA 200 MCG Rango de precios: desde €6.50 hasta €399.95

Perdigones IDRA-21 de 10 mg

IDRA-21 Pellets properties

Sinónimo : 1,1-dióxido de 7-cloro-3-metil-3,4-dihidro-2H-1,2,4-benzotiadiazina
CAS Número : 22503-72-6
Fórmula :C8H9ClN2O2S
Masa molar :232,6 g/mol
Pureza : >97%

Rango de precios: desde €13.50 hasta €398.58

* La información de esta página es un resumen y no pretende abarcar toda la información disponible sobre este medicamento. No abarca todos los posibles usos, instrucciones, precauciones, interacciones farmacológicas ni efectos adversos, ni sustituye la experiencia y el criterio de su profesional de la salud.

IDRA-21 10 MG Pellets – Scientific Description & User Manual

Descripción del Producto

IDRA-21 (gránulos de 10 mg)  is a potential  AMPA receptor potentiator  belonging to the class of  nootropic and neuroprotective research chemicals . It works by enhancing glutamate-induced signaling in the brain, which may lead to improved cognitive function, neuroplasticity, and potentially neurorecovery.

These pellets are  highly pure (≥98%) , standardized dosed and intended solely for  scientific research and preclinical studies .


Uses & Applications

IDRA-21 is being studied for its possible effects on:

  1. Cognitive Enhancement  – ​​May increase alertness, learning ability, and memory consolidation.

  2. Neuroprotection  – Potential protective effect in neurodegenerative diseases (e.g. Alzheimer’s, stroke).

  3. Neurological Recovery  – May Promote Synaptic Plasticity After Brain Injury.

  4. Investigación científica  – Study of AMPA receptor modulation and glutamate signaling.

⚠ Not approved for human or veterinary use – For in vitro and controlled preclinical studies only.


Dosage & Safety Guidelines

  • Investigational dosage (in vitro/preclinical):  5–20 mg/kg  (depending on model).

  • Pellet Solution:  Can be dissolved in  distilled water or DMSO  for experiments.

  • Administración:  Orally (animal models) or directly in cell cultures.

  • Frecuencia:  Single dose for acute effect; long-term studies require careful monitoring.

🚨 NB:

  • No human application  – No safety data for human use.

  • High doses may cause neuroexcitotoxicity.

  • Avoid combination with other glutamate modulators.


Desventajas y riesgos

  • Overstimulation of neurons  (risk of excitotoxicity in case of overdose).

  • Possible anxiety or agitation  in susceptible models.

  • Limited long-term data  on tolerance and adverse effects.

  • Not suitable for chronic use  without extensive toxicity studies.


Preguntas frecuentes (FAQ)

1. Is IDRA-21 legal in the Netherlands?

Yes, but only for  investigación científica . It doesn’t fall under the Opium Act, but it’s also not approved as a medicine.

2. How exactly does IDRA-21 work?

It  enhances the AMPA receptor response , making glutamate signaling longer and more intense. This can lead to improved synaptic communication.

3. Can IDRA-21 be compared to other nootropics?

It has a unique mechanism of action, but  similar targets as racetams or ampakines  (e.g. Sunifiram).

4. Are there any known interactions?

  • NMDA antagonists  (e.g. memantine) – Potentially adverse effects.

  • GABAergic agents  (e.g., benzodiazepines) – May reduce anxiolytic effects.


Informe de laboratorio y control de calidad

  • HPLC analysis:  ≥98% purity .

  • No detectable heavy metals or solvent residues .

  • Homogeneous pellet formulation  for consistent dosing.

  • Batch certification  available for research institutions.


Recommended Research Scenarios

  1. Cognitive studies  – Effects on memory and learning in animal models.

  2. Neuroprotective research  – Potential role in ischemic injury (stroke models).

  3. Electrofisiología  – AMPA receptor response measurements in neuronal cultures.

🔬 For controlled laboratory use only – No recreational use!